CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
Cancer Research and Treatment. 2018;50(3):691-700.   Published online 2017 July 6    DOI: https://doi.org/10.4143/crt.2017.280

Excel Download

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
Lung Cancer: Targets and Therapy. 2016;83   Crossref logo
Link1

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
PLoS ONE. 2014;9(12):e114008   Crossref logo
Link1

Lorlatinib Salvages CNS Relapse in ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated with Crizotinib and High-Dose Brigatinib
Clinical Lung Cancer. 2018;   Crossref logo
Link1 Link2

Estimating the Budget Impact of Crizotinib for Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Argentina
Value in Health. 2014;17(3):A74   Crossref logo
Link1 Link2

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment. 2018;50(3):691-700   Crossref logo
Link1 Link2 Link3

Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2014;15(3):e33-e35   Crossref logo
Link1 Link2

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib
Cancer. 2013;120(5):664-674   Crossref logo
Link1 Link2

Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma
Thoracic Cancer. 2015;7(1):3-8   Crossref logo
Link1

FACTORS ASSOCIATED WITH CRIZOTINIB EFFICACY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING DIFFERENT ALK FUSION VARIANTS
Respirology. 2018;23:288-289   Crossref logo
Link1 Link2

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
BMC Cancer. 2016;16(1):   Crossref logo
Link1 Link2 Link3 Link4

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.